Cytori Cell Research Institute, Inc. (3750.T)

949.00 -1.00 (-0.11%) At close: 03:15PM JST

Cytori Cell Research Institute, Inc.

Otemachi Park Building, 1-1-1 Otemachi
7th floor Chiyoda-ku
Tokyo 100-0004
Japan
81 3 6860 5701
https://www.cytori.co.jp

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 64

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Yoshihiro Hoshino	President, CEO & Representative Director	N/A	N/A	1957

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.

Corporate governance

Cytori Cell Research Institute, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.